Opexa Therapeutics, Inc., a drug delivery company based in The Woodlands, Texas, has been making significant progress in researching and developing Tcelna®, a breakthrough T-cell immunotherapy for multiple sclerosis (MS). The company recently announced they have reached their enrollment mark for conducting a Phase IIb clinical trial to test Tcelna as a viable…
SPMS
Recommended Posts
- Over 70% of MS patients in rehab take 5 or more medications, study finds
- New research project to explore how women with MS experience menopause
- MS progression is unpredictable, but I’m learning to adapt
- Lucid-MS moves toward clinical trial in US that will enroll MS patients
- With MS, movement can be one of the greatest teachers